PeptideLabs Logo
PeptideLabs
质量文档记录
Back to all 64 profiles
No uniform peptide protocol未获 FDA/EMA 批准

Community protocol · Selank + Semax

Selank + Semax: community information and evidence, clearly separated.

A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.

Also known as: SK + XA · Selank/Semax blend

Sources checked: 27 August 2026

重要安全与责任声明

本页记录并评估网络社区信息,不构成医疗或治疗建议、个体咨询,也不是使用邀请。

No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.

Quick context

Selank + Semax

社区常将其与压力及认知宣称联系起来;该混合物的临床获益与安全性尚未证实。

This entry is not a single peptide, or its use depends on diagnosis, product form or composition. A blanket peptide dose would be misleading.

Amounts, timing and cycles

No uniform peptide protocol

This entry is not a single peptide, or its use depends on diagnosis, product form or composition. A blanket peptide dose would be misleading.

Amount status

Different amounts circulate online; no regulator-confirmed safe or effective dose exists.

Profile evidence level: anecdotal.

Timing

Community claims about time of day, fasting windows or training intervals are not validated clinical standards.

No individual recommendation.

Cycle/duration

Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.

No individual recommendation.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

复配与 U-100 换算

No generic calculator

No responsible U-100 conversion can be made for blends or vaguely named products until each component amount, total volume and verified composition are unambiguous.

No responsible U-100 conversion can be made for blends or vaguely named products until each component amount, total volume and verified composition are unambiguous.

Mechanism and research questions

Non-standardised blend of two experimental neuropeptides

Selank + Semax is classified as “Non-standardised blend of two experimental neuropeptides”. 社区常将其与压力及认知宣称联系起来;该混合物的临床获益与安全性尚未证实。 This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

神经肽混合物

这项研究考察两种各自处于实验阶段、作用于神经系统的肽如何被商家一起营销,类似于将两种未经共同测试的独立工具组合成一套。研究大多关注单独的物质,而非其组合。

02

抗焦虑信号传导

这项研究考察某肽如何影响动物模型中的应激和焦虑反应,类似于观察动物在陌生环境中是否保持更加平静。测量指标包括行为测试和应激激素水平。

03

神经保护信号传导

这项研究考察某物质是否能保护神经细胞免受压力或损伤,例如在细胞模型中缺氧后的情况。在实验室条件下测量神经组织中的细胞存活率和信号标志物。

What communities discuss

These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.

组合与混合物讨论

用户分享自行组合的多种肽方案,并比较感知到的效果,而具体的组合方式往往从未经过研究。这类组合建议属于个人意见,而非经过验证的方案。

益智药论坛

人们讨论服用实验性神经肽后对注意力、情绪或压力感受的主观影响,通常基于个人日记。这类自我报告的印象极易受期望影响,无法替代对照研究。

商家营销宣传

商家常常以宽泛的功效宣称、与竞品的对比表格以及客户评价来推广产品。这类营销言论受销售利益驱动,并不构成独立的科学疗效证据。

Adverse effects and risk boundaries

  • 混合物叠加的不仅是潜在作用,还有不确定性、相互作用、剂量错误及稳定性问题。出现的作用无法可靠归因于某一成分。
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Exclusion groups and professional assessment

  • 在没有完整定性定量组成、批次检测及稳定性数据前,不应推导任何使用方式;所有合并疾病和药物都会增加风险。
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • 非标准化混合物没有经过验证的监测方案。单项化验无法使未知组成或相互作用变得安全。
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

轶事性

该组合的临床益处和安全性尚未得到证实。

Published evidence

相关说法主要依赖个人经历分享和商家宣传,而非对照研究。

该组合结合了两种各自均处于实验阶段的神经肽;该组合同样未经标准化。

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and error sources

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

未获 FDA/EMA 批准

没有 FDA 或 EMA 批准的药品;有效性与安全性尚未确立。

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.